American Association for Cancer Research
15417786mcr120414t-sup-fig1.pdf (227.39 kB)

Supplementary Figure 1 from MYC-Induced Epigenetic Activation of GATA4 in Lung Adenocarcinoma

Download (227.39 kB)
journal contribution
posted on 2023-04-03, 17:47 authored by Inês C. Castro, Achim Breiling, Katharina Luetkenhaus, Fatih Ceteci, Simone Hausmann, Sebastian Kress, Frank Lyko, Thomas Rudel, Ulf R. Rapp

PDF file - 227K, GATA4 promoter analysis and in-vivo material used for next generation-sequencing



Human lung cancer is a disease with high incidence and accounts for most cancer-related deaths in both men and women. Metastasis is a common event in non–small cell lung carcinoma (NSCLC), diminishing the survival chance of the patients with this type of tumor. It has been shown that MYC is involved in the development of metastasis from NSCLC, but the mechanism underlying this switch remained to be identified. Here, we focus on GATA4 as a MYC target in the development of metastasis with origin in lung adenocarcinoma, the most common type of NSCLC. Epigenetic alterations at the GATA4 promoter level were observed after MYC expression in lung adenocarcinoma in vivo and in vitro. Such alterations include site-specific demethylation that accompanies the displacement of the MYC-associated zinc finger protein (MAZ) from the GATA4 promoter, which leads to GATA4 expression. Histone modification analysis of the GATA4 promoter revealed a switch from repressive histone marks to active histone marks after MYC binding, which corresponds to active GATA4 expression. Our results thus identify a novel epigenetic mechanism by which MYC activates GATA4 leading to metastasis in lung adenocarcinoma, suggesting novel potential targets for the development of antimetastatic therapy. Mol Cancer Res; 11(2); 161–72. ©2012 AACR.

Usage metrics

    Molecular Cancer Research



    Ref. manager